This is a working overview of Melanotan II, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
== Taxonomic distribution and evolutionary advantages == Action potentials are found throughout multicellular organisms, including plants, invertebrates such as insects, and vertebrates such as reptiles and mammals. Sponges seem to be the main phylum of multicellular eukaryotes that does not transmit action potentials, although some studies have suggested that these organisms have a form of electrical signaling, too. The resting potential, as well as the size and duration of the action potential, have not varied much with evolution, although the conduction velocity does vary dramatically with axonal diameter and myelination.
=== Governance style === Known as a very secretive leader, little is known publicly about how Xi makes political decisions, or how he came to power. Xi's speeches generally get released months or years after they are made. Xi has also never given a press conference since becoming paramount leader, except in rare joint press conferences with foreign leaders. The Wall Street Journal reported that Xi prefers micromanaging in governance, in contrast to previous leaders such as Hu Jintao who left details of major policies to lower-ranking officials. Reportedly, ministerial officials try to get Xi's attention in various ways, with some creating slide shows and audio reports. The Wall Street Journal also reported that Xi created a performance-review system in 2018 to give evaluations on officials on various measures, including loyalty. According to The Economist, Xi's orders have generally been vague, leaving lower level officials to interpret his words. Chinese state media Xinhua News Agency said that Xi "personally reviews every draft of major policy documents" and "all reports submitted to him, no matter how late in the evening, were returned with instructions the following morning." With regard to behavior of Communist Party members, Xi emphasizes the "Two Musts" (members must not be arrogant or rash and must keep their hard-working spirit) and the "Six Nos" (members must say no to formalism, bureaucracy, gift-giving, luxurious birthday celebrations, hedonism, and extravagance).
== Instruments and Technologies == The National Dope Testing Laboratory is equipped with state of the art technologies and the most modern equipment. The use of Gas Chromatography coupled with Mass Spectrometry (GC-MS) is the most common and the oldest technology being used worldwide for dope testing. Nowadays, the use of liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) has become quite widespread. This technique has helped detect the difficult drugs falling into various categories of banned substances and is becoming increasingly more important in the fight against doping. Apart from GC-MS and LC-MS/MS, the use of Gas Chromatography coupled with tandem Mass Spectrometry (GC-MS/MS) and Isotope-ratio mass spectrometry (IRMS) is also very prevalent in sports dope testing. Both GC-MS/MS and LC-MS/MS are used primarily to analyze urine samples. The analysis of the blood matrix requires a completely different type of equipment which is commonly used in hospital laboratories.
Sources: en.wikipedia.org
In his first reelection bid, Mizell defeated Democrat James G. White, 68,937 (58.1 percent) to 49,663 (41.9 percent). He was endorsed that year by Americans for Constitutional Action (ACA). Charles McManus, the ACA's president, said, "He has repeatedly stood for fiscal responsibility; firm responsible opposition to the Communists; and for law and order in our streets and institutions of learning." In a 1971 speech to Congress, Mizell voiced his support for MLB's antitrust exemption. "[T]hrough baseball, opportunities have been afforded to young men who otherwise would not have been able to fully enjoy the American dream. Baseball builds character into young men who are going to be the leaders of the future." In 1972, he trounced former Arkansas Congressman Brooks Hays, who had moved to North Carolina, 101,375 (64.8 percent) to 54,986 (35.2 percent). During this term, he was a cosponsor of House Resolution 6992, which proposed equal rights to broadcast media outlets for the chance to broadcast sporting events. In 1972, he chaired a committee that tried to set up a Billy Graham Crusade in Washington, D.C., in 1973. Mizell opposed the Appalachian Power Company's Blue Ridge Power Project, a plan to build two dams on the New River. He was concerned about the project's impact: "Changing the basis for this environmental destruction from ‘pollution‐dilution’ to ‘power crisis’ does not lessen or eliminate the environmental destruction itself...Just as much land will . . . be flooded.
(2007) developed appreciative inquiry (AI), which is an integrated, organizational-level methodology for approaching organizational development. Appreciative inquiry is based on the generation of organizational resourcefulness, which is accomplished by accessing a variety of human psychological processes, such as: positive emotional states, imagination, social cohesion, and the social construction of reality. A relatively new practice in the workplace is recruiting and developing people based on their strengths (what they love to do, are naturally good at and energises them). Standard Chartered Bank pioneered this approach in the early 2000s. More and more organisations are realising the benefit of recruiting people who are in their element in the job as opposed to simply having the right competencies for the job. Aviva, Morrisons (a large UK supermarket) and Starbucks have all adopted this approach. Psychologist Howard Gardner has extensively researched the merit of undertaking good work at one's job. He suggested young generations (particularly in the United States) are taught to focus on the selfish pursuit of money for its own sake, although having money does not engender happiness, and psychological studies show that there is a strong correlation between the wealthy and experience of intensively negative emotions.
The opening of the Iron Curtain between Austria and Hungary at the Pan-European Picnic on 19 August 1989 set in motion a peaceful chain reaction, at the end of which there was no longer an East Germany and the Eastern Bloc had disintegrated. After the picnic, which was based on an idea by Otto von Habsburg to test the reaction of the USSR and Mikhail Gorbachev to an opening of the border, tens of thousands of media-informed East Germans set off for Hungary. Erich Honecker dictated to the Daily Mirror for the Pan-European Picnic: "Habsburg distributed leaflets far into Poland, on which the East German holidaymakers were invited to a picnic. When they came to the picnic, they were given gifts, food and Deutsche Mark, and then they were persuaded to come to the West." The leadership of the GDR in East Berlin did not dare to completely block the borders of their own country and the USSR did not respond at all. Thus the bracket of the Eastern Bloc was broken. Following the summer of 1989, by early November refugees were finding their way to Hungary via Czechoslovakia or via the West German embassy in Prague. On 30 September, following negotiations with East Germany and the Soviet Union, the West German Foreign Minister Hans-Dietrich Genscher went to the Prague embassy to personally inform the thousands of refugees that they were allowed to leave for West Germany.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.